1 Min Read
April 20 (Reuters) - Knight Therapeutics Inc:
* KNIGHT THERAPEUTICS ANNOUNCES CANADIAN REGULATORY APPROVAL FOR PROBUPHINE™ FOR OPIOID DRUG DEPENDENCE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.